A pilot trial of deferiprone for neurodegeneration with brain iron accumulation
Open Access
- 26 July 2011
- journal article
- clinical trial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 96 (11), 1708-1711
- https://doi.org/10.3324/haematol.2011.043018
Abstract
Deferiprone was shown to reverse iron deposition in Friedreich’s ataxia. This multi-center, unblinded, single-arm pilot study evaluated safety and efficacy of deferiprone for reducing cerebral iron accumulation in neurodegeneration with brain iron accumulation. Four patients with genetically-confirmed pantothenate kinase-associated neurodegeneration, and 2 with parkinsonism and focal dystonia, but inconclusive genetic tests, received 15 mg/kg deferiprone bid. Magnetic resonance imaging and neurological examinations were conducted at baseline, six and 12 months. Chelation treatment caused no apparent hematologic or neurological side effects. Magnetic resonance imaging revealed decreased iron accumulation in the globus pallidus of 2 patients (one with pantothenate kinase-associated neurodegeneration). Clinical rating scales and blinded video rating evaluations documented mild-to-moderate motor improvement in 3 patients (2 with pantothenate kinase-associated neurodegeneration). These results underline the safety and tolerability of deferiprone, and suggest that chelating treatment might be effective in improving neurological manifestations associated with iron accumulation.Keywords
This publication has 16 references indexed in Scilit:
- Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trialMovement Disorders, 2011
- Clinical and genetic delineation of neurodegeneration with brain iron accumulationJournal of Medical Genetics, 2008
- T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulationNeurology, 2008
- Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulationMovement Disorders, 2008
- Selective iron chelation in Friedreich ataxia: biologic and clinical implicationsBlood, 2007
- Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulationAnnals of Neurology, 2006
- New Advances in Iron Chelation TherapyHematology, 2006
- Genetic, Clinical, and Radiographic Delineation of Hallervorden–Spatz SyndromeThe New England Journal of Medicine, 2003
- Homozygosity mapping of Hallervorden–Spatz syndrome to chromosome 20p12.3–p13Nature Genetics, 1996
- The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1′ ol]-2-methyl-3-hydroxypyridin-4-one in the ratToxicology, 1996